

IFW

S/N 10/625,152



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: David B. Agus

Examiner: Unknown

Serial No.: 10/625,152

Group Art Unit: 1614

Filed: July 23, 2003

Docket: 67789-019

Title: USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE  
CANCER

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 04-0258 in order to have this Information Disclosure Statement considered.

**INFORMATION DISCLOSURE STATEMENT**

Serial No :10/625,152

Filing Date: July 23, 2003

Title: USE OF BENZOTHIOPENES TO TREAT AND PREVENT PROSTATE CANCER

---

Page 2

Dkt: 67789-019

Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

In accordance with the waiver of 37 C.F.R. § 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and publication for all U.S. national patent applications filed after June 30, 2003, only copies of the foreign references and other documents are enclosed. May 9, 2005

Respectfully submitted,  
DAVIS WRIGHT TREMAINE LLP

By 


Seth D. Levy

Registration No. 44,869

865 South Figueroa Street  
Suite 2400  
Phone: (213) 633-6869  
Facsimile: (213) 633-6899

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9th day of May, 2005.

Seth D. Levy


  
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/625,152
Filing Date	July 23, 2003
First Named Inventor	Agus, David
Group Art Unit	1614
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 67789-019

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	---------------------	------------------	---	---

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	EP-0652004	10/13/1994			
	WO-9845288	10/15/1998			

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		NEUBAUER, B., et al., "Comparative Antitumor Effects of Hormonal Ablation, Estrogen Agonist, Estrogen Cytotoxic Derivative, and Antiestrogen in the PAIII Rat Prostatic Adenocarcinoma", Cancer Research 52, 4663-4671	
		NEUBAUER, B., et al., "Raloxifene (LY156758) Produces Antimetastatic Responses and Extends Survival in the PAIII Rat Prostatic Adenocarcinoma Model", The Prostate 27:220-229 (1995)	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached